Speed up the access to and/or uptake of innovative Mpox Vaccines
Planned
The competition has not been announced yet.
- Deadline
- Mar 4, 2025Expired
- Agreement
- Buying services
- Estimated value
- €4.9Mover 3 years
Brief
The subject of this call for tenders is the evaluation of the immunogenicity of a booster dose, including different routes of administration (intradermal vs. subcutaneous) and the appropriate timing of the booster dose, for the Modified Vaccinia Ankara - Bavarian Nordic Vector (MVA-BN) vaccine. The services to be provided shall include the conduct of scientific study(s)/clinical trial(s) addressing the opinions of the CT-CM Group (Clinical Trial Coordination Mechanism subgroup of the HERA Board) on the most urgent clinical trial needs for medical countermeasures against Mpox. In particular, the services to be contracted shall take into account the Group's advice on priority clinical trials for vaccines, the understanding of existing knowledge gaps and support to policy actions that can be taken by the EU and/or its Member States to ensure preparedness and response capacity in the context of the 2024 Mpox outbreak, which was declared a Public Health Emergency of International Concern by the World Health Organization on 14 August 2024.
Statistikk og markedsundersøkelser
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
From the notice
The subject of this call for tenders is the evaluation of the immunogenicity of a booster dose, including different routes of administration (intradermal vs. subcutaneous) and the appropriate timing of the booster dose, for the Modified Vaccinia Ankara - Bavarian Nordic Vector (MVA-BN) vaccine. The services to be provided shall include the conduct of scientific study(s)/clinical trial(s) addressing the opinions of the CT-CM Group (Clinical Trial Coordination Mechanism subgroup of the HERA Board) on the most urgent clinical trial needs for medical countermeasures against Mpox. In particular, the services to be contracted shall take into account the Group's advice on priority clinical trials for vaccines, the understanding of existing knowledge gaps and support to policy actions that can be taken by the EU and/or its Member States to ensure preparedness and response capacity in the context of the 2024 Mpox outbreak, which was declared a Public Health Emergency of International Concern by the World Health Organization on 14 August 2024.
Contact
hadea-procurement@ec.europa.eu- PlanningType
- 73000000Main codeResearch and development services and related consultancy services
- 73300000Design and execution of research and development